Wire · operational-macro
Moderna jumps as FDA flu-shot approval reinforces recent business momentum
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 August 2026 · Fusion42 review
The FDA approved Moderna's mRNA-based seasonal flu vaccine, mFLUSIVA, marking the company's first approved flu shot and expanding its commercial respiratory portfolio ahead of the 2026-2027 flu season. This approval builds on Moderna's regulatory progress alongside its COVID and RSV vaccines and supports future combination vaccine plans.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 6 Aug 2026 and 12 Aug 2026.
◆ ◆ The Wire takeaway
You need to reconsider market timing and partnerships now that Moderna’s flu vaccine clearance unlocks new respiratory market access beyond COVID. This approval stakes out a stronger claim for combination vaccines, shifting competitive moves in respiratory biotech.
◆ Coverage
9 sources · first reported 6 Aug 2026 · latest 12 Aug 2026
◆ Related on Wire
◆ Topics